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ABSTRACT 
 
Lipoprotein Subclass Analysis by Immunospecific Density Gradient Ultracentrifugation. 
(December 2008) 
Sandy M. Lester, B.S., Stephen F. Austin State University 
Chair of Advisory Committee: Dr. Ronald D. Macfarlane 
 
Apolipoprotein C-1 (apo C-1) enriched HDL has been described as an atherogenic form 
of HDL associated with an increased risk for cardiovascular disease (CVD). The 
objective of the present study was to develop a rapid method for the separation, 
purification, and characterization of Apo C-1 from serum.  We isolated and characterize 
HDL subclasses from individuals with and without angiographically-proven CVD who 
have elevated and normal-to-low HDL-C levels.  
 Ultracentrifugation was linked with immunoaffinity separations for the specific 
separation of Apo C-1 enriched HDL from other lipoproteins.  A 50 µL sample of serum 
is diluted in TRIS HCl buffer (pH 7.5) and incubated with CNBr-activated Sepharose 
(Amersham) containing antibodies to apo C-1 (Academy Bio-medical Company). The 
apo C-1-depleted serum is removed by centrifugation and all apo C-1-containing 
lipoproteins are released from the Sepharose beads at pH 2. The apo C-1-depleted 
sample and the apo C-1-containing sample were ultracentrifuged to obtain a lipoprotein 
density profile in the absence and presence of apo C-1.  Density Lipoprotein Profiling 
(DLP) gives relevant information of lipoproteins, such as density and subclass 
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characterization, and is a novel approach to purify apo C-1-enriched HDL.  An 
additional advantage of this approach is that lipoprotein-a (Lp(a)), which is often an 
interfering component in the HDL density region, is eliminated.  
Results show feasibility that these methods could be used in a clinical setting, 
was achieved.  This measurement may yield a precise and quantitative profile of the 
distribution of apo C-1 for all lipoprotein particles including HDL. 
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CHAPTER I 
 
INTRODUCTION 
 
What Is Cardiovascular Disease? 
The heart consists of muscle, called myocardium that pumps blood; arteries that supply 
blood to the heart muscle; and valves to ensure that the blood is pumped in the correct 
direction. At any point in the pumping process, or in any part of the heart, something can 
go wrong. The diseases and conditions affecting the heart are collectively known as 
heart disease. [1] 
 Coronary heart disease means that blood flow through the coronary arteries has 
become impaired. A more general term that includes non-coronary arteries is 
cardiovascular disease (CVD).  The most common way such obstructions develop is 
through a condition called atherosclerosis, a largely preventable type of CVD. The 
actively contracting heart muscle needs a steady supply of oxygen and nutrients, carried 
through blood vessels or coronary arteries, to function. Over the course of a person’s 
lifetime — usually starting in early childhood — arteries, whose inner lining is normally 
smooth, can slowly become clogged with clumps of fats, cholesterol, and other material, 
called atherosclerotic plaques. The inner walls of arteries become slowly narrower 
because of a buildup of these plaques, importantly, rupture of a plaque can occur 
suddenly and the subsequent formation of a blood clot around the ruptured plaque may  
_________________  
This thesis follows the style of Biochimica et Biophysica Acta. 
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completely occlude the artery.  As a result, the blood containing oxygen and nutrients 
traveling to the heart muscle is blocked off and causes myocardial ischemia. As less 
blood and oxygen reaches the heart, it cannot function normally, and provokes overt 
physical consequences. [1, 2] 
Lipoproteins and Cardiovascular Disease 
The 2006 report on CVD by the American Heart Association (AHA) confirmed CVD as 
the leading cause of mortality in America. At least one in every three American adults 
has a form of Cardiovascular Disease (CVD). Cardiovascular diseases include heart 
disease, stroke, high blood pressure, heart failure and several other conditions including 
arrhythmias, atrial fibrillation, cardiomyopathy and peripheral arterial disease. [2]   
 CVD has been the leading cause of death in the United States every year since 1900 
except during the 1918 flu epidemic.   In 2004, the age-adjusted CVD death rate per 
100,000 persons was 288.0, compared to 307.7 deaths per 100,000 people in 2003.   In 
2005, CVD was listed as the underlying cause of death in 869,724 cases, compared to 
911,163 deaths in 2003.   Cancer was the second-leading cause of death, responsible for 
553,888 lives lost. Stroke, when considered separately from other CVD, was the nation’s 
third-leading killer totaling 150,074 deaths, followed by accidents at 112,012 fatalities.  
CHD, even when considered separately from other cardiovascular diseases, was still by 
far the nation’s single leading cause of death totaling 451,326 fatalities.  Although the 
full statistics for 2008 are not in at this time, from January 1, 2008 to May 20, 2008, 
250,735 people have been killed by CVD; 210,937 people died because of cancer; and 
57,556 deaths are attributed to stroke. [3] Atherosclerosis, the major cause of CHD, is 
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the narrowing, inflammation, and endothelial cell dysfunction of the coronary arteries 
due to fatty build-up of plaque. The death rate from Coronary Heart Disease in America 
has dropped 30.2% in the last ten years. Cardiovascular disease (CVD) death rates are 
declining, but CVD is still the number one cause of death in the United States, and 
according to the most recent data from the American Heart Association’s Heart Disease 
and Stroke Statistics – 2008 Update, the risk factor control remains a challenge for 
many. 
 In 2001, the National Cholesterol Education Program (NCEP) published a report 
on the detection, evaluation, and treatment of high cholesterol in adults. [4] One of the 
major causes of CHD is an elevated level of low-density lipoprotein (LDL) cholesterol. 
The first step in risk assessment is a measurement of LDL cholesterol as a part of 
lipoprotein analysis.  NCEP suggests that adults, ages 20 and older, should have a fasting 
lipoprotein profile performed once every five years. [4] 
Major risk factors for Coronary Heart Disease are [5]: 
• LDL cholesterol higher than 160mg/dL 
• Total cholesterol higher than 200mg/dL 
• High Density Lipoprotein (HDL) cholesterol lower than 40mg/dL, but above 
60mg/dL 
In addition to elevated LDL cholesterol, other known risk factors are [5]: 
• Cigarette smoking 
• Obesity 
• Hypertension 
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• Family history of heart disease 
• Age (men ≥ 45 years; women ≥ 55 years) 
Background on Lipoproteins 
Lipids are essential for cellular structure, cell signalling, and energy provision in the 
human body.  Highly hydrophobic lipids cannot travel freely in the aqueous plasma.  
Lipoproteins are the way that intact lipids are transported throughout the body.  
Lipoproteins are psuedo-micellar in structure comprised of proteins known as 
apolipoproteins and lipids. [5]  The lipid components are cholesterol, cholesterol esters, 
phospholipids, and triacylglycerols. (See Figure 1)  Lipoproteins differ in protein/lipid 
distribution, and vary from chylomicrons containing 98% lipids, to mature HDL that 
contains 50 % lipids.  The hydrophobic lipid core consists of triacylglycerols and 
cholesterol esters, whereas the surface of the lipoprotein particle is a combination of 
apolipoproteins, phospholipids, and cholesterol.  Table 1 summarizes the compositional 
differences between lipoprotein classes. [5] 
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Figure 1: Structure of a lipoprotein.  This diagram illustrates the architecture of 
lipoproteins; a core of water insoluble compounds, triacylglycerols and cholesteryl 
esters, and an amphiphatic membrane of phospholipids, free cholesterol and 
apolipoproteins. [6] 
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Table 1: Composition of Human Serum Lipoproteins 
Component Chylomicrons VLDL IDL LDL HDL 
Phospholipids    
(Weight %) 
6-9 16-20 20-24 24-30 24-30 
Free Cholesterol 
(Weight %) 
1-3 4-8 8-9 9-12 2-5 
Cholesteryl Esters 
(Weight %) 
3-6 9-13 13-28 28-30 10-20 
Triglycerides 
(Weight %) 
82-86 50-60 12-50 7-11 4-5 
Proteins  
(Weight %) 
1-2 8-11 11-20 20-22 41-58 
Density (kg/L) 0.93-1.006 0.95-1.006 1.006-1.019 1.019-1.063 1.063-1.21
 
 
The protein moiety of lipoproteins is comprised if various apolipoproteins.  (See 
Table 2)  Apolipoproteins are present in each lipoprotein and serve as enzyme activators, 
ligands for cell receptors, and aid in metabolism of the lipoprotein.   
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Table 2: Human Apolipoproteins Present in Lipoproteins and  
Their Molecular Mass 
Apolipoprotein Lipoprotein Molecular Mass 
Apo A-I HDL, Chylomicrons 28,000 
Apo A-II HDL, Chylomicrons 17,000 
Apo A-IV Chylomicrons,  transfers to HDL 46,000 
Apo B-100 LDL, VLDL, IDL 550,000 
Apo B-48 Chylomicrons 260,000 
Apo C-I VLDL, HDL, Chylomicrons 6,600 
Apo C-II VLDL, HDL, Chylomicrons 8,900 
Apo C-III VLDL, HDL, Chylomicrons 8,750 
Apo D HDL 19,300 
Apo E VLDL, IDL, HDL, Chylomicrons 34,000 
 
 
The major functions of the apolipoproteins are lipid transport between the liver 
and the peripheral tissues and metabolic control via the activation or inhibition of 
enzymes, seen below in Figure 2. 
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Figure 2: Lipid transport between the liver and peripheral tissues. Pathways 
involved in the generation and conversion of HDL. ABC1 indicates adenosine 
triphosphate-binding cassette transporter 1; Apo A-I, apolipoprotein A-I; Apo E, 
apolipoprotein E; CE, cholesteryl ester; CETP, cholesteryl ester transfer protein; 
HDL, high-density lipoprotein; HL, hepatic lipase; IDL, intermediate-density 
lipoprotein; LCAT, lecithin-cholesterol acyltransferase; LDL, low-density 
lipoprotein; LDL-R, low-density lipoprotein receptor; LDL-RRP, low-density 
lipoprotein receptor-related protein; Lyso PC, lysophosphatidylcholine; PC, 
phosphatidylcholine; PGN, proteoglycans; PL, phospholipids; PLTP, phospholipid 
transfer protein; SR-B1, scavenger receptor B1; UC, unesterified cholesterol; and 
VLDL, very-low-density lipoprotein. [7] 
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Biomarkers in the Blood 
Rapid developments in biochemical markers of cardiovascular disease have 
revolutionized the approach to diagnosis and management of acute coronary syndromes 
in recent years. [8] 
Known Biomarkers in Cardiovascular Disease [9, 10]: 
• Creatine Kinase, anything above normal levels of 25 to 200 U/L 
(units per liter) 
• Myoglobin, anything above normal levels of 50 ng/mL  
• Lactate Dehydrogenase, anything above a typical range is 105 - 333 
IU/L (international units per liter). 
• Blood levels of C-reactive protein, anything above 4.9mg/L 
• Oxidized LDL 
Continuing Search for Risk Markers 
Traditional risk factors—smoking, obesity, cholesterol, etc.—can only tell a person so 
much about the possibility developing heart disease later in life. It is well known, that 
more than 50 percent of all future vascular events occur in people without overt 
hyperlipidemia, an elevation of lipids in the bloodstream. Studies have also shown that 
20 to 25 percent of all future heart attacks occur in people with only one traditional 
factor. [8] This is why it is important to detect risk factors early in life to help prevent 
future risks of heart disease. 
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Apolipoprotein C-1 Enriched High Density Lipoprotein 
Apolipoprotein C-1 (apo C-1), a 6.6-kDa plasma protein, has a basic pI because of its 
high lysine content (16 mol %) and lack of histidine, tyrosine, cysteine, and 
carbohydrate. [11] It contains 57 amino acids, and is synthesized in the liver; it’s 
secreted following a co-translational cleavage of 26 amino acid peptide from the N-
terminal. [12] Normal apo C-1 concentration in circulation is 6 mg/dL.  Apo C-1 is a 
component of very-low-density (VLDL), intermediate density (IDL), and high-density 
(HDL) lipoproteins. [13, 14] 
Apo C-1 contains alpha-helix regions that contribute to lipid binding.  Apo C-1 
activates both LCAT and LPL and may inhibit the clearance of triglyceride rich 
lipoproteins by altering the binding of apolipoprotein E (apo E) to the LPR receptor in 
the liver. 
Problematic apo C-1 displaces apolipoprotein E (apoE) from VLDL and IDL and 
thereby decreases their clearance from plasma. [11]  ApoC-1decreases the binding of B-
VLDL to its remnant receptor (LDLR)—LDL receptor related protein—and apoE 
mediated binding of VLDL and IDL to the LDLR.  Apolipoprotein C1 inhibits 
cholesterol ester transfer protein and phospholipase A2 activity.  It also stimulates 
lecithin cholesterol acyl transferase up to 80% of that of apolipoprotein A-1 (Apo A-1). 
[5] 
A. Apolipoprotein C-1 Enriched HDL and Atherosclerosis 
Over the past decade, research has indicated that premature plaque rupture due to death 
of aortic smooth muscle cells (ASMC) is a major contributor of atherosclerosis. [15, 16]  
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Treatment of ASMC with apo C-1 or apo C-1-enriched HDL particles induces apoptosis, 
and therefore may contribute to the complications of atherosclerosis. [17] 
Transgenic mice, expressing a wild-type human apo C-1 background or in 
combination with knockout of apo E or LDLR, were studied to determine the effect of 
apo C-1 without apo E. This combination created a hyperlipidemia effect, or high levels 
of lipids in the bloodstream, caused by delayed remnant clearance.[11, 16, 18-20]  
Research on apo C-1 transgenic mice with an apo E-null background proved positive for 
apo C-1-enriched HDL and an increase in atherosclerosis.  However, it was the apo C-1-
enriched HDL, not VLDL, which had an inhibitory effect on the hepatic lipase. [18] 
In humans, it has been shown that a significant enrichment of apo C-1 in VLDL 
remnants can contribute to early signs of atherosclerosis in normolipidemic patients with 
coronary artery disease. [21, 22] 
B. Apolipoprotein C-1 Enriched HDL in SGA Infants 
It has been reported that low birth weight is associated with increased risk for CVD in 
adults. [23] Therefore, Kwiterovich and coworkers studied lipoproteins present at birth 
in cord blood of low birth weight infants. Results showed that a significant number of 
infants have increased levels of large HDL particles and also HDL particles enriched in 
apoC-1.  
As seen in Figure 3, patients can be placed in different “groups” based on the 
gray intensity scale of apo C-1-enriched HDL that appears in their lipid profile.  These 
groups are classified as Groups 0 to 3 based on the intensity of the area between the LDL 
and HDL in a serum profile.   
 12 
Group 0 infants had no inflection above the baseline (no detectable Apo C-1 
Enriched HDL); Group 1 had a small bump above the baseline (1 to 5 pixels on scale) 
(possible Apo C-1-enriched HDL); Group 2 had a peak above baseline in the range of >5 
to <50 pixels on scale (probable Apo C-1-enriched HDL); and Group 3 had a peak 
greater than 50 pixels on scale (elevated Apo C-1-enriched HDL). [17] 
 
 
 
 
 
 
 
Figure 3: Lipid profiles depicting Apo C-1-enriched HDL groups.  [17] 
 13 
The basis for this thesis is to locate this probable apo C-1-enriched HDL particle 
with a density range of 1.062 and 1.072 g/mL.  The peak for lipoprotein(a) (Lp(a)) is 
between 1.050 and 1.100g/mL, [24] which could occur at the same density as apo C-1-
enriched HDL. Therefore, it is important to future research to obtain Lp(a) values. 
Ultracentrifugation as an Analytical Tool for Separation of Lipoproteins 
Measurement of VLDL, LDL, and HDL has been a useful research tool in studies of 
lipoprotein metabolism, pathophysiology, and CVD development.  There are several 
methods, including sequential flotation and rate zone centrifugation and equilibrium 
density centrifugation, used to separate the different lipids based on density, size, and 
apolipoprotein composition. 
Equilibrium Density Gradient Ultracentrifugation 
An equilibrium density gradient ultracentrifugation will be utilized.  In density gradient 
ultracentrifugation, the sample is mixed with a continuous gradient solvent and 
centrifugation occurs until the lipoproteins form discrete bands according to their density 
(usually 6 hrs depending on the solvent used). During centrifugation, the solvent 
generates a gradient, and the proteins migrate to where their density is the same as the 
gradient material. Isopycnic means “same density”. [25] Isopycnic density gradient 
ultracentrifugation effectively separates the lipoproteins present in serum into 
chylomicrons, VLDL, IDL, LDL, and HDL. (Fig 4)   
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As one moves down the Ultracentrifugation (UC) tube, the density increases and 
the particle size decreases from chylomicrons to HDL.  The lipoprotein fractions also 
differ in lipid to protein ratios, apolipoprotein constituents, and are constantly changing 
in size, density, and components.                           
Advantage of Cs2CdEDTA Salt as a Density Gradient Forming Solute 
Solutions of metal ion complexes of ethylenediaminetetraacetic acid salts (EDTA) were 
described as a novel approach to produce self—generating density gradients from a 
homogenous solution during ultracentrifugation. [26-28]  The cation influences gradient 
properties, with the cesium cadmium EDTA (Cs2CdEDTA) salt, using cesium and 
cadmium as counterions, forming a less steep density gradient than other EDTA 
complexes. Within this density profile HDL and protein components of serum shift to a 
higher position on the tube coordinate scale, i.e. will give a better separation between 
HDL subclasses. (See Figure 4) 
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Figure 4: Lipoprotein profiles showing the separation differences between NaBiEDTA 
(A) and Cs2CdEDTA (B). Each 6µL serum sample were spun at 5°C in 1100µL of the 
respective gradients, 10µL of 1mg/mL NBD C6-ceramide, and 44µL distilled water for 6 
hours at 120,000rpm. 
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NBD-C6 Ceramide Stain for Lipoprotein Imaging 
The structure of NBD-C6 ceramide (6-((N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)amino)-
hexanoyl) sphingosine), as shown in Figure 5, is a widely used fluorescent probe for the 
staining of lipids. In the case of NBD-C6 ceramide, it has emission at 536nm, absorption 
at 462nm and EC at 22,000. [29] NBD-labeled lipids are very stable and have suitable 
fluorescence properties such as: environmentally sensitive, self-quenching at high 
concentrations, minimal interference with other biological fluorphores. However, in 
water solutions NBD can suffer from photobleaching, limiting its fluorescence lifetime. 
[30]  Studies done on cellular membranes show that NBD is found at the polar regions of 
the membrane, whether it is the head or tail of the phosholipid molecule. [30] The 
hydrophobic tail of the NBD-C6 ceramide interacts with the surface of the lipoprotein 
and deep into the lipid core.  The quantitive incorporation of the NBD molecule to 
lipoproteins was studied and showed that when the hydrophobic tail of the NBD 
molecule is imbedded in the lipoprotein molecule, the molecule fluoresces. [26] If the 
NBD is not imbedded in a lipoprotein molecule, there is no fluorescence.   
 
 
                              
Figure 5: Structure of NBD C6-ceramide [29] 
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Capillary Electrophoresis and Lipoproteins 
Capillary electrophoresis (CE) has recently emerged as a powerful separation technique 
for biomolecules.  CE has the advantages of obtaining complete separations with high 
efficiency in a relatively short amount of time.  The main advantage of CE is that 
preparation of samples is quick and easy. 
Apolipoproteins have a high affinity for detergents; therefore, adding detergents 
in the CE background buffer can influence electrophoretic behavior of proteins.  Sodium 
dodecyl sulfate (SDS) is a very common detergent because it has two main effects on 
apolipoproteins. First, it eliminates protein aggregation by competing for protein-protein 
interactions. Second, it binds to the lipoproteins to alter their size, shape, and net 
charge—resulting in a modification of electrophoretic mobilities. [31, 32] 
Antibodies and Immunoprecipitation 
Antibodies, or Immunoglobulins (Ig), are proteins of molecular weight of approximately 
150,000 to 900,000 kD. The basic structural unit of an antibody is a glycoprotein 
containing two light chains and two heavy chains, which are connected by disulfide 
bridges, thus forming a capital “Y” shape. Each chain is divided into regions, or 
domains, consisting of around 110 amino acid residues. The light chain has two domains 
and the heavy chain has four. The N-terminal domain, the tip of the arms of the "Y" on 
both the heavy and light chain, is known to be a variable in amino acid sequence 
composition and is thus called a variable domain; the other domains are called constant 
for a similar reason. [33-35]  (See Figure 6)  
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Figure 6: Basic monomer structure of an immunoglobulin molecule. (Adapted from 
[33]) 
 
 
The “Y” end of the Ig binds to the antigens (Fab portion, so called because it is 
antigen binding), and the other end is responsible for biological activity (Fc, so called 
because it is the crystallizable portion of the molecule). [33]  The crystallizable portion 
of the antibody will bind to the Sepharose bead, therefore orienting the antibody such 
that the Fab portion will bind to the antigen optimally. [36] 
Antibodies are capable of recognizing so many antigens because of the variable 
region of the Fab.  Both the variable and constant regions of the antibody are genetically 
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coded. There are two classes (isotypes) of the light chain called kappa and lambda. 
Heavy chains have five different isotopes which divide the Ig’s into five different 
classes, each with different effector functions (in humans IgG1-4, IgA1-2, IgD, IgM, 
IgE). Each class of heavy chain can combine with either of the light chains, thus giving 
the different possibilities of binding to different antigens. [33, 37] 
Immunoprecipitation is a procedure by which peptides or proteins react with an 
antibody, and are then captured and are removed from solution. These peptides or 
proteins are selected by the antibody based upon a physical (molecular weight, color 
change, isoelectric point, etc.) or chemical (polysaccharide, proteins, etc.) characteristic. 
[33, 38-41] Contrary to the procedure’s name, the precipitate contains only the protein of 
interest, thus leaving proteins not of interest in the supernatant.  (See Figure 6)  When 
this is the case, antigen retrieval plays a key role.  [42] 
Antigen Retrieval (AR), as developed by Shi et al. in 1991, [43] is a high-
temperature heating method to recover the antigens from tissue sections previously 
masked by formalin fixation. Microwaves, pressure cooker, autoclaving and steam 
heating are most commonly used. [44]  High-temperature heating methods are the most 
important factor for the retrieval of antigens and yields better results when compared to 
other methods.  The pH of the antigen retrieval solution is another important factor to 
success in recovering antigens. Some antigens require heating along with a change in pH 
to achieve the strongest results.   [37, 45] 
To further advance the results of immunoprecipitation, scientists no longer 
relying on just a “color change” when studying antibody-antigen reactions.  [36, 46]  
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Agar and agarose gels are quickly becoming common place tools in various areas of 
emerging biotechnology.  Agar, a mixture of galactan derivatives extracted from red 
seaweeds, has limitations because of its ionic moieties.  Isolated from agar, agarose (see 
figure 7), however, has a greater gel strength, gelling and melting temperatures, and 
electrical properties that are better suited to various analytical techniques involved in 
immunoprecipitation. [47]  Agarose gel particles (See Figure 7) are sold under trade 
names such as Sepharose (Pharmacia) and Bio-Gel (Bio-Rad).   
 
 
 
 
 
 
 
Figure 7: Agarbiose: basic repeating unit of agarose, (1, 3)--D-galactopyranosyl [1, 4]-
3, 6 anhydro--L-galactopyranose. Adapted from [47] 
 
 
 
 
An antibody is bound physically or chemically to the agarose particle interacts 
specifically with antigens of interest, and thus remove these particles from complex 
solutions. (See Figure 8) 
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Figure 8: Binding of antigens to antibodies. [33] 
 
 
 
 
 
Immunoprecipitation is a technique that can be formatted to fit one’s needs. 
CNBr-activated Sepharose is a highly cross-linked agarose mixture that is reacted with 
cyanogen bromide (CNBr).  This coupling makes the gel more rigid and allows for large 
proteins and other molecules to be directly coupled to the medium.  Multi-point 
attachment of proteins allows for good chemical stability, high yield in products, and 
reproducibility of the gel. Mean particle size is 90µm, with the size ranging from 45 to 
165µm.  The Sepharose beads are 4% agarose and are spherical in structure. [48] 
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Application of Antibodies with Lipoprotein Research 
Immunoprecipitation can be used for many different purposes. Among these are: (1) 
determination of molecular weight and isoelectric points of precipitated proteins by 
SDS-PAGE [49], (2) verification that an antigen of interest is synthesized by a specific 
tissue [44], (3) characterization of the type of carbohydrate present on glycoproteins 
[46], (4) identification of individual’s drug use through forensics [36], (5) determination 
of heroin metabolites in urine by capillary electrophoresis [35] , and (6) study of 
lipoprotein remnants in human serum [50].  Although studies have been done with 
antibodies and lipoproteins, most of these studies isolated lipoproteins utilizing more 
than one antibody and more than one analytical technique—SDS-PAGE, CE, 
immunoaffinity chromatography, mass spectrometry, ultracentrifugation, and ELISA. 
[35, 37, 45, 46, 50-52]   
For this research, immunoprecipitation will be utilized with one specific 
antibody, Anti-Apolipoprotein C1, in order to isolate apolipoprotein C-1 in serum 
obtained from patients with or without CVD.  This research will show that patients with 
CVD have an apoC-1-enriched HDL, as detected in the recovered lipoprotein profile.  
However, non-CVD patients will not have any apoC-1 recovered after antigen retrieval, 
and will have no recovered HDL profile. 
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CHAPTER II 
 
EXPERIMENTAL 
 
This chapter focuses on the description of the experimental settings for all the 
procedures developed or applied for the research reported in this thesis. Detailed 
protocols for all experimental sections can be found in Chapter IV of this thesis. 
Blood Draw and Serum Collection 
A. Materials 
Serum samples were obtained by venipuncture into a 7mL, vacuum tube with a sterile 
interior containing STT gel and clot activator (Beckton Dickinson Vacutiner Systems, 
Franklin Lakes, NJ).  
B. Methods 
Blood from normolipidemic subjects was drawn into a Vacutainer-brand series 
collection tubes following a 12-h fast. Serum was separated from red blood cells by 
centrifugation at 3200rpm for 20 minutes at 4°C. The supernatant (serum) was aspirated 
from the red blood cells, aliquotted into 250µL increments, and used immediately or 
stored at -86°C until used. 
Coupling Antibody to CNBr-activated Sepharose 
A. Materials 
Apolipoprotein C-1 Antibody solution was purchased through Academy Biomedical 
Sciences in Houston, TX.  The CNBr-Sepharose beads were purchased from Amersham 
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Biosciences.  The following solutions were prepared and used during the binding of 
antibody to the Sepharose beads and the binding of serum to the antibody-Sepharose gel: 
(1) Coupling buffer—0.1M NaHCO3 and 0.5M NaCl, pH 9.0, (2) 1mM HCl, (3) 
Blocking buffer—1M Tris-Base, pH 9.0 in coupling buffer, (4) low pH wash buffer—
0.1M HCl, 0.5M NaCl, and (5) 0.05M Tris-HCl.  
B. Methods 
An optical density reading at 280nm (OD280) of the antibody solution was taken to 
determine the protein concentration in the antibody solution.  62.5µL coupling buffer 
(0.1M NaHCO3 and 0.5M NaCl, pH 9.0) was then added to 125µL antibody solution 
obtained. [17]  The Sepharose beads were mixed with 1mM HCl and allowed to swell 
for approximately 15 minutes at room temperature.  Supernatant was then removed, and 
the Sepharose beads were washed with 1mM HCl solution for 1 minute, with this 
process repeated twice.  
The next two steps were done with no pausing in between.  Swollen agarose 
beads were washed with 5mL coupling buffer to prepare for the addition of the antibody-
coupling buffer solution, and after the addition, the tube was rotated gently at room 
temperature for 4 hours.  After the beads settled, the supernatant was removed, and the 
OD280 was taken. If the OD280 is at least 10-fold lower than before coupling, one can 
continue with the procedure. If OD280 is not at least 10-fold lower than in step 1, 
coupling did not proceed as expected.  The primary cause for failure was not transferring 
gel to antibody solution quickly enough.   
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The coupled medium was washed twice with 1mL coupling buffer, prior to 
addition of 1mL blocking buffer (1M Tris-Base, pH 9.0 in coupling buffer) and 
incubation for 2 hours at room temperature.  The supernatant was then removed, and the 
gel was washed 4x, alternating washes between low pH wash buffer (0.1M HCl, 0.5M 
NaCl) and high pH wash buffer (coupling buffer). The first and fourth washes were 
saved, and the OD280 of each was checked to determine that all antibody in solution was 
removed, thus showing an OD280 reading below ~0.01. 
Coupling Serum to Sepharose-Antibody Gel  
The AB-Sepharose gel, that was freshly made and washed with coupling buffer, was 
mixed with 50µL serum and 600µL 0.05M Tris-HCl in a 1.5mL Eppendorf tube. The 
tube was gently rotated for 4 hours at 1400rpm at room temperature.  After rotation, the 
Sepharose gel was allowed to settle and the depleted serum, approximately 600µL, was 
removed.  Using a 3,000 molecular weight cut-off (MWCO) filter the supernatant, 
containing everything that did not bind to the AB, was concentrated for UC separation. 
(See Figure 9)  
Recovering Serum from the Sepharose-Antibody Gel  
After removing the depleted serum from the AB-Sepharose gel, the beads were washed 
twice with coupling buffer to ensure removal of residual, bound serum in the Eppendorf 
tube.  Afterwards, 600µL of 1mM HCl was added to the beads. The tube was gently 
rotated at 1400rpm for 5 hours at 37°C.  After rotation, the Sepharose gel was allowed to 
settle and the recovered lipoproteins, approximately 600µL, was removed.   
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The Sepharose-AB gel was washed with coupling buffer twice and then stored in 
20% ethanol to prevent microbial growth at 4°C. 
 
 
 
 
Figure 9: Schematic showing the steps involved for immunoprecipitation. 
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Separation of Lipoprotein Particles by Single Spin Ultracentrifugation 
 
A. Materials 
A 0.175M and 0.300M solution of Cs2CdEDTA was used to form the density gradient 
used for the separation of lipoprotein classes. The various EDTA complexes were 
synthesized from H4EDTA, the appropriate alkali carbonate, and the heavy metal 
carbonate. The reagents were combined stoichiometrically in 100mL of DI H2O, 
followed by a two hour reflux, yielding a clear solution.  Sodium carbonate or cesium 
carbonate was then added to the clear solution to bring the final pH range to 6-7. The 
final solution volume was reconstituted to 100 mL to account for evaporation during 
reflux to give stoichiometric solutions with a final concentration of 0.200 M. [28] A 10% 
(w/v) solution of sodium-bismuth-EDTA (NaBiY) in water was also used as a density 
gradient. NaBiY is commercially available (E086, TCI America, Portland, OR, USA).  
In either density gradient, serum samples were stained with NBD C6-ceramide as 
a 1 mg/mL or 2 mg/mL solution in dimethyl sulfoxide (DMSO, 99.9%, MX1458-6 
Burdick &Jackson, Muskegon, MI, USA).  NBD C6-ceramide (NBD) was purchased 
from Molecular Probes (Eugene, OR). 
Each sample was pipetted into an ultracentrifugation tube (1.5 mL, thick-walled, 
polycarbonate, Beckman-Coulter, Palo Alto, CA).  Ultracentrifugation was carried out in 
a Beckman Optima TLX tabletop ultracentrifuge equipped with a 30° fixed angle TLA 
129.2 rotor.   
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B. Methods 
 
Lipoproteins were separated based on their hydrated densities as discussed previously. 
[26, 28]  Six microliters of Apo C-1 enriched HDL serum samples were individually 
mixed with 10 µL of 1 mg/mL NBD, 1100 µL of 0.175 M Cs2CdEDTA or 10% 
NaBiEDTA, and 44 µL of distilled water. The samples were allowed to stand for 30 
minutes at 5°C so the NBD C6-ceramide could be incorporated into the lipoproteins. A 
1000 µL volume of each sample was transferred to an ultracentrifuge tube. Both density 
gradients were formed by ultracentrifugation for 6 hours, 120,000 rpm and 5°C. [26, 27] 
Layering Ultracentrifugation Tubes 
After the UC spin, each tube was layered with 200µL distilled water to further separate 
the buoyant TRL from the dense TRL found in the meniscus. 
Digital Analysis 
A fluorescence imaging system was developed in order to improve sensitivity and 
versatility to the lipoprotein fingerprinting method as previously reported. The light 
source used was a Fiber-Lite MH –100 Illuminator (MH100A, Edmund Industrial 
Optics). The camera used was a digital color microscope camera (S99808, Optronics, 
Goleta, CA). The camera and the light source were placed orthogonally from each other 
on an optical bench. A tube holder, suspended by a post/post holder, was placed 8 cm 
away in order to collimate the excitation beam.  A gain of 1.0000 and an exposure time 
of 15.8 ms were chosen using the accompanying Micro Fire camera software. A blue-
violet excitation filter (BG-12, Schott, Edmund Industrial Optics) with a bandwidth at 
407 nm and a yellow emission filter (OG-515, OEM, Edmund Industrial Optics) with a 
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bandwidth centered at 570nm were chosen to match the excitation and emission of NBD 
C6-ceramide. 
Lipoprotein Fraction Collection after Ultracentrifugation 
A. Materials 
By using a high-speed thin blade (0.254 mm wide) scroll saw (Model 1672, 16 inches, 2-
speed, Dremel, Racine, WI) and liquid nitrogen, lipoprotein fractions could be collected 
and saved for further analysis. 
B. Methods 
After ultracentrifugation and imaging, the ultracentrifugation tubes containing Apo C-1 
Enriched HDL serum were slowly frozen in liquid nitrogen, without disturbing the 
gradient. [53]  By cutting the tube at the appropriate positions with a high-speed thin 
blade scroll saw, lipoprotein fractions were collected. Cut positions were determined 
from the profile obtained from the digital imaging software. 
C18 Solid Phase Extraction, Desalting, and Delipidation 
A. Materials  
The proteins in VLDL, LDL, and HDL were delipidated and purified using a tC18 Light 
cartridge (Sep-Pack, 36805, Waters, Milford, MA, USA). Also used were trifluoroacetic 
acid (TFA, T-6508, Sigma, St. Louis, MO, USA), and acetonitrile (ACN, 99.8%, 
AX0145-1, EM Science, Gibbstown, NJ, USA).  Solutions of 0.1% TFA in distilled 
water and 0.1% TFA in acetonitrile were prepared and used for this experiment. 
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B. Methods 
Apo C-1 enriched HDL fractions were prepared for capillary electrophoresis (CE) and 
kept intact by removing the density gradient medium from the fraction by ultrafiltration 
in a 100,000 MWCO filter (Millipore).  The samples were filtered with CE background 
buffer seven times for 3 minutes at 6,000 rpm.   
Apo C-1 enriched HDL fractions were delipidated using a tC18 Light Cartridge.  
The tC18 cartridge was conditioned with 5 mL 0.1% TFA in ACN slowly, allowing no 
air to enter the cartridge, and then with 5 mL 0.1% TFA in water, allowing no air to 
enter the cartridge.   
The sample, mixed with 0.1% TFA and water, was slowly loaded onto the 
cartridge. The cartridge was rinsed with 0.1% TFA in water to remove any salts from the 
cartridge. The proteins are then eluted with four 50 µL 0.1% TFA in ACN aliquots with 
1 mL air pushed through the cartridge.  The 2nd through 4th aliquots were collected and 
combined.  The combined aliquots were immediately Speed-Vacuumed to dryness and 
then reconstituted to 50µL with the CE buffer of 12.5mM Sodium Borate, 3.5mM 70% 
SDS, and 20% ACN.   
Apolipoprotein C-1 HDL Characterization by Capillary Electrophoresis 
A. Materials  
All capillary electrophoresis experiments were performed using a P/ACE MDQ 
instrument (Beckman Coulter, Fullerton, CA).   
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B. Methods 
Table 3 shows a capillary electrophoresis time program used for the separation of 
lipoproteins in the Apo C-1 enriched HDL fractions and for characterization of the Apo 
C-1 standard used in perfecting the immunoprecipitation protocol.  Protein samples were 
kept at a temperature of 20°C during testing.  
 
 
Table 3: Capillary Electrophoresis Time Program 
Step Time Function Duration 
1  Buffer Rinse 2.00 min 
2  Inject EOF 5.00 s 
3  Inject Sample 5.00 s 
4  Inject Buffer 2.00 s 
5 0.00 Separate-Voltage 20 kV 30.00 min 
6 0.00 Auto Zero  
7 30.00 Stop Data  
8 30.00 Rinse 0.1N NaOH 1.00 min 
9 31.00 Rinse dH2O 1.00 min 
10 32.00 End  
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CHAPTER III 
 
RESULTS AND DISCUSSION 
 
Influence of Cs2CdEDTA vs. NaBiEDTA on Lipoprotein Profiles 
In the Cs2CdEDTA solute system (seen in Figure 10B and 10C), the slope of the density 
gradient was less steep than the NaBiEDTA system (as seen in Figure 10A), causing the 
HDL and protein regions of the lipoprotein profile to shift to a higher position on the 
tube coordinate scale, thus further separating the LDL and HDL regions. There was 
essentially no difference in the LDL region of the lipoprotein profiles between these two 
solute systems, but the intensity of the VLDL peak in the Cs2CdEDTA system was 
elevated.  In each case due to the inherently higher molecular weight of the counterion, it 
can be seen that Cs+ solutions yield a steeper density profile than those containing the 
Na+.  
It was also noticed that when a serum sample is spun in a solute containing Cs+, 
the corresponding density of the lipoprotein subclasses were higher than those spun in a 
solute containing the Na+ ion. At a pH of 7, lipoproteins are macromolecular anions, so 
the Na+ and Cs+ ions will form an ionic atmosphere around them and increase their 
density relative to their natural state. Since Cs+ is heaver than the Na+, the density of the 
lipoprotein can be greatly altered by substituting the counterion of the EDTA complex. 
These findings suggest that the ionic atmosphere configuration is retained under the 
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influence of the forces operating during ultracentrifugation as the lipoproteins migrate to 
their isopycnic positions.   
Because there were concerns with the region between the LDL and HDL, the 
Cs2CdEDTA density gradient was selected for further study.  Using this particular 
density gradient increased recovery of the lipoprotein fractions because the LDL and 
HDL fractions are more widely separated allowing more room to cut between the 
lipoprotein classes.  
Now that it has been established to use Cs2CdEDTA density gradient, one must 
decide on what concentration. In Figure 10, the Cs2CdEDTA is at 0.175M. (See Figure 
10B) When the molarity is increased to 0.300M (Figure 10C), the solution becomes 
denser and further separates the HDL.  This higher molarity is useful when the HDL 
subclasses want to be separated. One disadvantage to this particular density gradient is 
that the VLDL, IDL, and LDL are all sandwiched together and are inseparable for 
further analysis.  
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Figure 10: Ultracentrifugation profiles showing differences in densities and separations 
of LDL and HDL between 0.200M NaBiEDTA, 0.175M Cs2CdEDTA and 0.300M 
Cs2CdEDTA.  Profiles show 0.200M NaBiEDTA (A), 0.175M Cs2CdEDTA (B), and 
0.300M Cs2CdEDTA (C).  Each 50µL serum sample were spun at 120,000rpm at 5°C in 
1100µL of the respective gradients, 10µL of 1mg/mL NBD C6-ceramide, and 44µL 
distilled water for 6 hours. 
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Coupling Apolipoprotein C-1 Standard to Sepharose-Apolipoprotein C-1 Antibody 
After attaching the Apolipoprotein C-1 antibody to the CNBr-Sepharose beads as shown 
in the previous chapter, one had to make sure that the Sepharose-Antibody beads did in 
fact remove the Apo C-1 in solution.  Therefore, 50µL of Apolipoprotein C-1 Standard 
(Human Apo C-1, 31P-101, 0.1mg, Academy Biomedical Company, Houston, Texas) 
[54]was added to 600µL 0.05M Tris-HCl in a 1.5mL Eppendorf tube.  The Apo C-1 
standard was collected from fresh human plasma that has been purified by a series of 
ultracentrifugations in which the VLDL was isolated from human plasma.  Purity was 
verified by SDS-PAGE.  [54] An optical density reading at 280nm (OD280) of 300µL of 
the Apo C-1 Standard-Tris-HCl solution was taken to determine the starting protein 
concentration being added to the system.   
 
Apolipoprotein C-1 STD + NaN3 Tris-HCL  OD280 = 0.187 
 
The tube containing the Apo C-1 Standard and Tris-HCL solution was gently 
rotated for 4 hours at 1400rpm at room temperature.  After rotation, the Sepharose gel 
was allowed to settle and the depleted serum, approximately 600µL, was removed.  An 
optical density reading at 280nm was taken of the supernatant to determine if the Apo C-
1 Standard was successfully attached to the Antibody-Sepharose beads and removed 
from the solution.   
 
Depleted Apolipoprotein C-1 STD + NaN3 Tris-HCL  OD280 = 0.005 
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After the supernatant was removed, the gel was washed twice with coupling 
buffer to ensure that all residual traces of Apo C-1 Standard and NaN3 Tris-HCl were 
removed.  Afterwards, 600µL of 1mM HCl was added to the beads. The tube was gently 
rotated at 1400rpm for 5 hours at 37°C.  After rotation, the Sepharose gel was allowed to 
settle and the recovered Apo C-1 Standard, approximately 600µL, was removed and an 
optical density reading was taken. 
 
Recovered Apolipoprotein C-1 STD + HCL  OD280 = 0.183 
 
Although the absorbances of each solution show the Apo C-1 standard being 
removed and recovered, each sample was analyzed by Capillary Electrophoresis as a 
second method to prove the theory.  After all supernatants were collected, each was 
Speed Vacuumed to dryness and reconstituted using 50µL of the CE buffer consisting of 
12.5mM NaBorate, 3.5mM SDS (70%), and 20% ACN.  Each electropherogram is 
shown below in Figures 11-13.  
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Figure 11:  Electropherogram of apolipoprotein C-1 standard. Background electrolyte 
consisted of 12.5mM Sodium Borate, 3.5mM SDS, and 20% (v/v) acetonitrile, pH 9.25.  
EOF marker consists of 0.05% DMSO with a 5sec 0.5psi injection.  Under these 
conditions this Apo C-1 Standard has an effective mobility of -26.3x10-5 cm2/Vs. 
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Figure 12:  Electropherogram of depleted apolipoprotein C-1 standard. Background 
electrolyte consisted of 12.5mM Sodium Borate, 3.5mM SDS, and 20% (v/v) 
acetonitrile, pH 9.25.  EOF marker consists of 0.05% DMSO with a 5sec 0.5psi 
injection.  The only peak detectable is that of the EOF. 
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Figure 13:  Electropherogram of recovered apolipoprotein C-1 standard. Background 
electrolyte consisted of 12.5mM Sodium Borate, 3.5mM SDS, and 20% (v/v) 
acetonitrile, pH 9.25.  EOF marker consists of 0.05% DMSO with a 5sec 0.5psi 
injection.  Under these conditions this Recovered Apo C-1 Standard has an effective 
mobility of -26.1x10-5 cm2/Vs. 
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Influence of Serum Volume on Antibody-Sepharose Lipoprotein Profiles 
Serum volume can affect the lipoprotein intensity and the separation differences.  Too 
small a volume and the intensity of the peaks are weakened; too concentrated a serum 
volume and the intensity and separation of peaks increases. An experiment was designed 
to test this theory using 6µL, 50µL, and 60µL of serum in 0.175M Cs2CdEDTA. The 
results are shown in Figure 14.  All three experiments used the same reagents: 1100µL 
0.175M Cs2CdEDTA, 10µL 1mg/mL NBD C6-ceramide, and XµL distilled water.  NBD 
was added in the same volume and concentration so that any changes in intensities were 
due to the difference in serum volumes.  The amount of distilled water (XµL) is 
dependent on the volume of serum that is added to the UC tubes. The distilled water and 
serum total must be equal to a volume of 80µL. Therefore, for a 6µL serum sample, the 
volume of distilled water must be equal to 74µL.    
After a six-hour ultracentrifugation spin at 120,000rpm at 5°C, a huge increase in 
intensities was noticeable for all lipoproteins between the 6µL and the 50µL runs, but 
not so much between the 50µL and 60µL runs.  In fact, there was a huge decrease in the 
dense HDL intensity in the 50µL and 60µL runs.  Both the buoyant and dense HDL 
fractions were higher in intensities in the 50µL spins; therefore, all immunoprecipitation 
will be run with 50µL serum. 
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Figure 14: Ultracentrifugation profiles showing volume differences using 6µL (A), 50µL 
(B), and 60µL (C) of human serum.  Each sample was spun at 120,000rpm for 6 hours at 
5°C in 1100µL of 0.175M Cs2CdEDTA, 10µL of 1mg/mL NBD C6-ceramide, and 74µL 
(A), 30µL (B), and 20µL (C) distilled water. 
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Influence of 1mM HCl on Lipoprotein Profiles 
A major step in the immunoprecipitation experiment is the recovery of the captured 
lipoproteins. As stated in Chapter I, antigen retrieval will be done with a technique 
utilizing a change in pH. [44] Because the immunoprecipitation reactions were run in 
neutral and basic solutions, a change to an acidic pH opened the “Y” and released the 
antigen from the antibody.    
Using the acid as the antigen retrieval solution, one should be certain that only 
the antigens will be removed from the precipitate.  Therefore, 100mL of 1mM HCl was 
added to 0.05g pre-swollen and washed Sepharose beads without the apo C-1-antibody.  
The beads were pre-swollen and washed so that no absorption of acid would be seen; i.e. 
volume of acid in will equal volume of solution out.   Data was collected by recording 
the absorbance at 280nm.  Table 4 below shows the results of the experiment. 
 
 
Table 4: Effect of 1mM HCl on Sepharose Beads without Antibody 
   ABS at 280nm  
1mM HCl (Blank)   0.000  
1mM HCl after Sepharose addition   0.077  
 
 
 
 
As seen in Table 4, the addition of 1mM HCl to the Sepharose beads brought a 
little amount of impurities off the beads.  If the acid had little effect on the beads, what 
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effect will the acid have on lipoproteins? To test this, 50µL serum was added to 80µL 
distilled water or 80µL 1mM HCl in addition to 1100µL 0.175M Cs2CdEDTA and 10µL 
1mg/mL NBD.  Each tube was mixed for 2 minutes and allowed to incubate for 30 
minutes before the UC spin. (See Figure 15A and 15B) To determine if the acid affected 
any lipoprotein subclasses (bTRL, dTRL, LDL-1, LDL-2, LDL-3, LDL-4, LDL-5, HDL-
2b, HDL-2a, HDL-3a, HDL-3b,and HDL-3c) [5], we decided to compare the coefficient 
of variation (CV) for all lipoprotein subclasses.  This was done by taking the standard 
deviation divided by the average and multiplying by 100.   A high CV means a high 
variation in lipoprotein subclasses, thus showing a change in lipoprotein structure due to 
acid digestion. (See Table 5) 
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Figure 15: Ultracentrifugation profiles depicting effects of HCl on serum.  UC profiles 
show (A) serum + 80µL dH2O and (B) serum + 80µL 1mM HCl with 1100µL 0.175M 
NaBiEDTA and 10µL 1mg/mL NBD C6-ceramide.  The UC spin was performed at 
120,000 rpm at 5°C for 6 hours. 
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Table 5: Relative Intensities, Averages, Standard Deviation, 
and the Coefficient Variation for Figure 15 [5] 
 
Serum + 
dH2O 
Serum + 
HCl Average Std Dev CV 
bTRL 2999.867 3399.673 3199.77 282.7055 8.835183 
dTRL 1939.28 2059.502 1999.391 85.00979 4.251784 
LDL-1 668.317 557.118 612.7175 78.62957 12.83292 
LDL-2 1723.393 1765.312 1744.3525 29.64121 1.699267 
LDL-3 2869.306 3076.634 2972.97 146.603 4.931198 
LDL-4 4092.985 4220.742 4156.8635 90.33784 2.173221 
LDL-5 1807.865 2068.403 1938.134 184.2282 9.505441 
HDL-2b 1364.946 1587.101 1476.0235 157.0873 10.6426 
HDL-2a 976.871 989.161 983.016 8.690342 0.884049 
HDL-3a 1691.838 1644.919 1668.3785 33.17674 1.988562 
HDL-3b 2161.459 2007.024 2084.2415 109.202 5.239414 
HDL-3c 1000.647 876.401 938.524 87.85519 9.360995 
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Influence of 37°C on Recovered Lipoprotein Profiles 
Along with a change in pH, heat also has an effect on the recovery of lipoproteins from 
antibodies. Compared to room temperature retrieval, will adding heat have any influence 
on increasing the intensities of the recovered lipoprotein profiles? To test this theory, 
600µL 1mM HCl was added to a freshly reacted Sepharose-AB-Lipoprotein sample and 
heated to 37°C for 5 hours while mixing on an orbital shaker at 1400rpm.  The 
Sepharose-AB beads were allowed to settle and the supernatant was collected and 
analyzed by ultracentrifugation in 0.175M Cs2CdEDTA for 6 hours at 5°C at a speed of 
120,000rpm.  (See Figure 16A and 16B) 
As seen in the data provided, heating the samples, along with changing the pH of 
antigen retrieval solution, increases the chances of releasing any lipoprotein that was 
captured during the binding process. Because it was shown that a change in pH and a 
change in heat hardly affected the lipoproteins, all clinical samples will undergo this 
combined antigen retrieval method.  
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Figure 16: Ultracentrifugation profiles of recovered lipoproteins using antigen retrieval 
methods such as changes in pH and temperature.  UC profiles show 1mM HCl for (A) 1 
hour at Room Temperature vs. (B) 5 hours at 37°C.  Profiles contained 50µL serum, 
1100µL 0.175M Cs2CdEDTA, 10µL 1mg/mL NBD C6-ceramide and 600µL 1mM HCl.  
Each spin was performed at 5°C for 6 hours at 120,000rpm. 
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Reproducibility of CNBr-activated Sepharose Gel 
In order to increase proficiency with clinical trials, a test to determine whether the AB-
Sepharose gel prepared could withstand more than one full experiment—addition of 
serum for 4 hours and then the recovery process—needed to be run.  To test this, an 
experiment was run using the same Sepharose-AB mixture and a patient’s serum twice 
through.  See Figure 17.   
As one can see, the AB-Sepharose gel took to both experiments well.  The 
meniscus and VLDL peaks vary because of the human error that was introduced into the 
sample when the UC tubes were layered with 200 µL distilled H2O.  Because both LDL 
and HDL profiles are identical, this informs us that we can run multiple samples with the 
same AB-Sepharose gel without having to make fresh gel for each trial.  This will help 
to save time, money, and resources. 
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Figure 17: Ultracentrifugation profiles showing reproducibility of CNBr-activated 
sepharose gel.  First (A) and Second (B) uses of Anti-Apolipoprotein C1-Sepharose gel.  
Profiles each show a baseline (black), depleted lipoproteins (blue), and recovered 
lipoproteins (red).  Each UC spin was performed with 1100µL 10%NaBiEDTA, 10µL 
1mg/mL NBD C6-ceramide, 50µL serum/supernatant at 120,000rpm at 5°C for 6 hours. 
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CHAPTER IV 
 
APPLICATION: APOLIPOPROTEIN C-1 CHARACTERIZATION IN CASE 
STUDIES 
 
The purpose of this chapter is to demonstrate the applicability of the methods developed 
during the course of this research. The protocols used in these samples were the same for 
all of them and were as detailed in Chapter II, the Experimental Section. 
Initial scientific interest in the study of apolipoprotein C1 enriched HDL started 
with a collaboration with Peter O. Kwiterovich, Jr. and Johns Hopkins involving small 
gestational age (SGA) infants.  [17]  After this research was deemed successful in the 
study of CVD in infants, it was asked as to whether or not the same apolipoprotein C1-
enriched HDL can be found in adults.  The main goal of this project was to develop a 
rapid, easy-to-use method for the characterization of Apo C-1distribution by density. 
The methods developed in this research were applied to a pilot clinical study involving 
patients from Scott & White Clinic in Temple, TX.  Criteria for each patient included: 
(1) normal or high HDL, (2) normal LDL, and (3) classification as either CVD or non-
CVD as determined by a team of doctors at Scott & White Clinic in Temple, TX.  
Patients were classified as either “Control” or “CVD” based on a previous angiogram 
done at Scott & White Clinic.   
Thirty patients were selected based on the above criteria, and their serum 
underwent immunoprecipitation reactions using the apolipoprotein C1-Antibody.  
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Baseline serum, depleted serum, and recovered serum samples were separated using the 
ultracentrifugation spin with fluorescent NBD C6-ceramide stain. Density profiles were 
constructed for each sample.  Figure 18 through Figure 35 show the density profiles for 
the baseline, depleted serum, and the recovered lipoproteins for six of the thirty samples.  
HDL2 and HDL3 subfractions are indicated in the profiles. 
Apo C-1 Characterization CVD Subject 1, 
High HDL2 and HDL3 Levels in Lipoprotein Density Profile 
Sample 1 was collected from a Cardiovascular patient who is a 75 year old Caucasian 
female with a family history of CVD.  Her cardiac risk factors are fairly minimal, but 
has had elevated LDL levels of 133 mg/dL.  HDL levels for this patient, at the time of 
the blood draw, were 84 mg/dL.   
The lipoprotein density profile of this subject shows a bump in the density region 
between LDL and HDL—labeled HDL2. (See Figure 18)  Classified as a cardiovascular 
patient, it is expected that if the HDL2 and HDL3 regions are Apo C-1 enriched, these 
two peaks will attach to the Apo C-1 Antibody on the Sepharose beads and disappear 
from the depleted serum lipoprotein profile.  As seen in Figure 19, what is shown in the 
supernatant after reaction with the Apo C-1 Antibody is LDL, VLDL and chylomicrons, 
and serum proteins.       
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Figure 18: Baseline ultracentrifugation profile for CVD patient 1.  Baseline profile 
shows serum before reaction with the Apo C-1 Antibody-Sepharose beads.  The UC 
profile contains 1100µL 0.3M Cs2CdEDTA, 10µL 1 mg/mL NBD C6-ceramide, 50µL 
serum, and 40µL distilled water at 120,000rpm at 5°C for 6 hours. 
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Figure 19: Depleted serum ultracentrifugation profile for CVD patient 1.  The UC profile 
contains 1100µL 0.3M Cs2CdEDTA, 10µL 1 mg/mL NBD C6-ceramide, 50µL 
supernatant, and 40µL distilled water at 120,000rpm at 5°C for 6 hours.  The supernatant 
was collected after reaction with Apo C-1 Antibody-Sepharose beads for 4 hours. 
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Figure 20 shows the Apo C-1 enriched VLDL, HDL2 and HDL3 that is recovered 
following a 5 hour spin with 1mM HCl wash at 37°C.  The lipoproteins that were 
recovered contained enough Apo C-1 that could attach to the antibodies and be pulled 
out of solution.  By changing pH and temperature, these lipoproteins were released from 
the antibody and analyzed by ultracentrifugation, and show a perfect case of apo C-1-
enriched HDL in human serum.  The shift in HDL2 and HDL3 in the recovered profile 
could be due to apo C-1 being pulled off HDL particles.  Further analysis and testing, by 
CE or MALDI-MS, would need to be done to determine if this is indeed what happened. 
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Figure 20: Recovered serum ultracentrifugation profile for CVD patient 1. The 
recovered lipoprotein profile shows HDL2 and HDL3 recovered by antigen retrieval 
based on change in pH and addition of heat.  Each UC profile contains 1100µL 0.3M 
Cs2CdEDTA, 10µL 1mg/mL NBD C6-ceramide, 50µL serum/supernatant, 40µL distilled 
H2O at 120,000rpm at 5°C for 6 hours. 
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Apo C-1 Characterization CVD Subject 2, 
High HDL and Lp(a) Levels in Lipoprotein Density Profile 
Sample 2 was collected from a cardiovascular Patient 2 that is a 72 year old, Caucasian 
male with high HDL (>160 mg/dL) and elevated Lp(a) levels—thus resulting in a 
elevated bump between the LDL and HDL in the baseline profile (Figure 21).  This 
“bump” between the LDL and HDL can be determined to be either Lp(a) or Apo C-1-
enriched HDL by using the Apo C-1 Immunoprecipitation procedures discussed in this 
thesis. 
Figure 22 shows the lipoprotein profile for the apolipoprotein C-1 depleted serum 
of CVD Patient 2.  Here, the apolipoprotein C-1 concentrations are noticed in the 
depleted volume of HDL2 and HDL3, but not in the VLDL or serum proteins.   
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Figure 21: Baseline ultracentrifugation profile for CVD patient 2.  Baseline profile 
shows serum before reaction with the Apo C-1 Antibody-Sepharose beads.  The UC 
profile contains 1100µL 0.3M Cs2CdEDTA, 10µL 1 mg/mL NBD C6-ceramide, 50µL 
serum, and 40µL distilled water at 120,000rpm at 5°C for 6 hours. 
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Figure 22: Depleted serum ultracentrifugation profile for CVD patient 2.  The UC profile 
contains 1100µL 0.3M Cs2CdEDTA, 10µL 1 mg/mL NBD C6-ceramide, 50µL 
supernatant, and 40µL distilled water at 120,000rpm at 5°C for 6 hours.  The supernatant 
was collected after reaction with Apo C-1 Antibody-Sepharose beads for 4 hours. 
 
 
 
 
As seen in Figure 23, when the solution’s pH and temperature was changed, 
HDL2, HDL3, VLDL, and serum proteins are recovered.  Recalling from Chapter I, Apo 
C-1 can be found in Chylomicrons, VLDL, HDL, and serum proteins.  This particular 
patient helps to show that Apo C-1, which is being pulled from multiple proteins in 
human serum, can be easily accessible to the Apo C-1 antibodies and/or is enriched on 
one or more particular lipoproteins. Although this patient has high levels of Lp(a) in his 
serum, it should be noted that there is also apo C-1-enriched HDL, as seen in the 
recovered lipoprotein profile, which may attributing to his heart conditions. 
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Figure 23: Recovered serum ultracentrifugation profile for CVD patient 2. The 
recovered lipoprotein profile shows HDL2 and HDL3 recovered by antigen retrieval 
based on change in pH and addition of heat.  Each UC profile contains 1100µL 0.3M 
Cs2CdEDTA, 10µL 1mg/mL NBD C6-ceramide, 50µL serum/supernatant, 40µL distilled 
H2O at 120,000rpm at 5°C for 6 hours. 
 
 
 
Apo C-1 Characterization CVD Subject 3, 
High Levels of HDL in Lipoprotein Density Profile with a History of CVD 
Sample 3 was collected from a cardiovascular male subject in his fifties with high LDL 
levels (>160 mg/dL).  Although Patient 3 has high levels of HDL, see Figure 24, these 
levels have not been enough to prevent significant cardiovascular disease.  This warning 
flag makes him a perfect candidate for the Apolipoprotein C-1 Immunoprecipitation 
protocol. 
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Figure 24: Baseline ultracentrifugation profile for CVD patient 3.  Baseline profile 
shows serum before reaction with the Apo C-1 Antibody-Sepharose beads.  The UC 
profile contains 1100µL 0.3M Cs2CdEDTA, 10µL 1 mg/mL NBD C6-ceramide, 50µL 
serum, and 40µL distilled water at 120,000rpm at 5°C for 6 hours. 
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Figure 25: Depleted serum ultracentrifugation profile for CVD patient 3.  The UC profile 
contains 1100µL 0.3M Cs2CdEDTA, 10µL 1 mg/mL NBD C6-ceramide, 50µL 
supernatant, and 40µL distilled water at 120,000rpm at 5°C for 6 hours.  The supernatant 
was collected after reaction with Apo C-1 Antibody-Sepharose beads for 4 hours. 
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As seen in Figure 26, by changing the solution’s pH and temperature, HDL2 and 
HDL3 is recovered in tact and with the same density peaks and separation as seen above 
in his baseline profile, Figure 24.  The shift in HDL2 and HDL3 in the recovered profile 
could be due to apo C-1 being pulled off HDL particles.  Further analysis and testing, by 
CE or MALDI-MS, would need to be done to determine if this is indeed what happened.  
The recovery of the HDL2 and HDL3 helps to conclude this patient is a CVD 
subject due to the apo C-1-enriched HDL being recovered versus the depleted-serum 
profiles showing no apo C-1 being recovered in the HDL regions. 
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Figure 26: Recovered serum ultracentrifugation profile for CVD patient 3. The 
recovered lipoprotein profile shows HDL2 and HDL3 recovered by antigen retrieval 
based on change in pH and addition of heat.  Each UC profile contains 1100µL 0.3M 
Cs2CdEDTA, 10µL 1mg/mL NBD C6-ceramide, 50µL serum/supernatant, 40µL distilled 
H2O at 120,000rpm at 5°C for 6 hours. 
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Apo C-1 Characterization Control Subject 1, 
High Levels of HDL3 in Lipoprotein Density Profile with a History of CVD 
Sample 4 was collected from a “control patient” who is a 58 year old Caucasian female 
with low HDL levels (<35 mg/dL) and a family history of CVD.  Her LDL levels were 
between 130-160 mg/dL.  As seen in her baseline profile, Figure 27, there is no “bump” 
between the LDL and HDL indicating no Lp(a) or HDL2.  It is her family history and 
recent angioplasty by Scott & White in Temple, TX, that has placed her as a control in 
this study.  
Figure 28 shows the lipoprotein profile for the apolipoprotein C-1 depleted serum 
of sample 4.  Here, the VLDL, LDL, HDL, and serum proteins all remain intact, 
showing no apo C-1-enriched particles that could be attached to the apo C-1-AB-
Sepharose beads.  As seen in Figure 29, when we change the solution’s pH and 
temperature, we recover no lipoproteins.  This particular patient helps to showcase that 
with a family history of CVD; there might be no other risk factors for CVD. 
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Figure 27: Baseline ultracentrifugation profile for control patient 1.  Baseline profile 
shows serum before reaction with the Apo C-1 Antibody-Sepharose beads.  The UC 
profile contains 1100µL 0.3M Cs2CdEDTA, 10µL 1 mg/mL NBD C6-ceramide, 50µL 
serum, and 40µL distilled water at 120,000rpm at 5°C for 6 hours. 
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Figure 28: Depleted serum ultracentrifugation profile for control patient 1.  The UC 
profile contains 1100µL 0.3M Cs2CdEDTA, 10µL 1 mg/mL NBD C6-ceramide, 50µL 
supernatant, and 40µL distilled water at 120,000rpm at 5°C for 6 hours.  The supernatant 
was collected after reaction with Apo C-1 Antibody-Sepharose beads for 4 hours. 
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Figure 29: Recovered serum ultracentrifugation profile for control patient 1. The 
recovered lipoprotein profile shows HDL2 and HDL3 recovered by antigen retrieval 
based on change in pH and addition of heat.  Each UC profile contains 1100µL 0.3M 
Cs2CdEDTA, 10µL 1mg/mL NBD C6-ceramide, 50µL serum/supernatant, 40µL distilled 
H2O at 120,000rpm at 5°C for 6 hours. 
 
 
 
 
Apo C-1 Characterization Control Subject 2, 
Low Levels of HDL in Lipoprotein Density Profile with a History of CVD 
Sample 5 was collected from a “control patient” who is a 47 year old female with a 
family history of CVD.  This Caucasian female is a smoker with high LDL levels greater 
than 160 mg/dL.  In previous years, her HDL has fallen below 35 mg/dL. As seen in her 
baseline profile, Figure 30, HDL2 connects LDL and HDL3.  Her risk factors—family 
history, smoking, high LDL levels, and low HDL levels—have placed her in this study.  
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Figure 30: Baseline ultracentrifugation profile for control patient 2.  Baseline profile 
shows serum before reaction with the Apo C-1 Antibody-Sepharose beads.  The UC 
profile contains 1100µL 0.3M Cs2CdEDTA, 10µL 1 mg/mL NBD C6-ceramide, 50µL 
serum, and 40µL distilled water at 120,000rpm at 5°C for 6 hours. 
 
 
When studying the apo C-1-depleted lipoprotein profile, the VLDL, LDL, HDL, 
and serum proteins all remain intact, although intensity and placement of the LDL has 
changed; there are no apo C-1-enriched particles that could attach to the apo C-1-AB-
Sepharose beads.  (See Figure 31)  As seen in Figure 32, when we change the solution’s 
pH and temperature, we recover no lipoproteins.  This particular patient helps to 
showcase that although there is a family history of CVD and high levels of “bad” LDL, 
apo C-1-enriched HDL might not be to blame for this patient’s heart problems. 
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Figure 31: Depleted serum ultracentrifugation profile for control patient 2.  The UC 
profile contains 1100µL 0.3M Cs2CdEDTA, 10µL 1 mg/mL NBD C6-ceramide, 50µL 
supernatant, and 40µL distilled water at 120,000rpm at 5°C for 6 hours.  The supernatant 
was collected after reaction with Apo C-1 Antibody-Sepharose beads for 4 hours. 
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Figure 32: Recovered serum ultracentrifugation profile for control patient 2. The 
recovered lipoprotein profile shows HDL2 and HDL3 recovered by antigen retrieval 
based on change in pH and addition of heat.  Each UC profile contains 1100µL 0.3M 
Cs2CdEDTA, 10µL 1mg/mL NBD C6-ceramide, 50µL serum/supernatant, 40µL distilled 
H2O at 120,000rpm at 5°C for 6 hours. 
 
Apo C-1 Characterization Control Subject 3, 
Low Levels of HDL2 and HDL3 in Lipoprotein Density Profile 
Sample 6 was collected from a “control patient” who is a 42 year old Caucasian, male 
with no family history of CVD. He has high levels of LDL and shows normal HDL 
levels in his baseline profile, Figure 33.  It is his “bump” between the LDL and HDL and 
his non-apparent risk factors that has placed him in this study.  
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Figure 33: Baseline ultracentrifugation profile for control patient 3.  Baseline profile 
shows serum before reaction with the Apo C-1 Antibody-Sepharose beads.  The UC 
profile contains 1100µL 0.3M Cs2CdEDTA, 10µL 1 mg/mL NBD C6-ceramide, 50µL 
serum, and 40µL distilled water at 120,000rpm at 5°C for 6 hours. 
 
 
When studying the apo C-1-depleted lipoprotein profile, the VLDL, LDL, HDL, 
and serum proteins all remain intact, although the VLDL intensity has decreased slightly 
and tube placement has changed; there are no HDL apo C-1-enriched particles that could 
attach to the apo C-1-AB-Sepharose beads.  (See Figure 34)  This shift in placement 
could indicate an apo C-1 particle being removed from the VLDL, as proven in Figure 
35 when solution’s pH and temperature was changed, some VLDL was recovered.  
Sample 6 helps to showcase that although there is a no family history of CVD and low 
levels of HDL, apo C-1-enriched HDL might not be the cause for this patient’s heart 
condition. 
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Figure 34: Depleted serum ultracentrifugation profile for control patient 3.  The UC 
profile contains 1100µL 0.3M Cs2CdEDTA, 10µL 1 mg/mL NBD C6-ceramide, 50µL 
supernatant, and 40µL distilled water at 120,000rpm at 5°C for 6 hours.  The supernatant 
was collected after reaction with Apo C-1 Antibody-Sepharose beads for 4 hours. 
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Figure 35: Recovered serum ultracentrifugation profile for control patient 3. The 
recovered lipoprotein profile shows HDL2 and HDL3 recovered by antigen retrieval 
based on change in pH and addition of heat.  Each UC profile contains 1100µL 0.3M 
Cs2CdEDTA, 10µL 1mg/mL NBD C6-ceramide, 50µL serum/supernatant, 40µL distilled 
H2O at 120,000rpm at 5°C for 6 hours. 
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CHAPTER V 
 
SUMMARY AND CONCLUSIONS 
 
The study reported here demonstrates the analytical power of linking ultracentrifugation 
with immunoaffinity separations for the characterization of serum lipoproteins.  The 
primary objective to this research was to develop a rapid method for the separation, 
purification, and characterization of Apo C-1-enriched HDL from human serum.  The 
objective was met by linking Apo C-1 Antibody with CNBr-activated Sepharose beads 
and using a density gradient ultracentrifugation method for lipoprotein separation. 
 Apolipoprotein C-1-enriched HDL was selectively removed from human serum 
by using a 50µL sample of serum that is diluted in TRIS HCl buffer (pH 7.5) and 
incubated with CNBr-activated Sepharose (Amersham) containing antibodies to apo C-1 
(Academy Bio-medical Company). The apo C-1-depleted serum is removed by 
centrifugation and all apo C-1-containing lipoproteins are released from the Sepharose 
beads at pH 2. The apo C-1-depleted sample and the apo C-1-containing sample were 
ultracentrifuged to obtain a lipoprotein density profile in the absence and presence of apo 
C-1.  Density Lipoprotein Profiling (DLP) gives relevant information of lipoproteins 
such as density and subclass characterization, and is a novel approach to purify apo C-1-
enriched HDL.  An additional advantage of this approach is that lipoprotein-a (Lp(a)), 
which is often an interfering component in the HDL density region, is eliminated.  
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Apolipoprotein C-1 was quantitatively removed from serum and recovered 
efficiently.  All apo C-1 recovered by the methods described in this thesis retained its 
inherent hydrated density.  Apo C-1 was purified by ultracentrifugation, and by utilizing 
an apo C-1 standard, characterization was achieved by capillary electrophoresis.  
The main objective of the research, to show feasibility that these methods could 
be used in a clinical setting, was achieved.  In conclusion, this methodology will yield a 
precise and quantitative profile of the distribution of apo C-1 for all lipoprotein particles 
including HDL. 
 
 70 
REFERENCES 
 
[1] J. Plutzky, P. Libby, Atherosclerosis and Heart Disease, in: A. Tonkin (Ed.), 
Taylor & Francis Group, London, 2003, pp. 1-12. 
[2] American Heart Association, Heart Disease and Stroke Statistics--2006 Update, 
American Heart Association, Dallas, TX, 2006, pp. 1-43. 
[3] H.-C. Kung, D.L. Hoyert, J. Xu, S.L. Murphy, Deaths: Final Data for 2005, 
National Vital Statistics Reports, vol. 56, National Center for Health Statistics, 
Hyattsville, MD, 2008. 
[4] S. Grundy, Implications of Recent Clinical Trials for the National Cholesterol 
Education Adult Treatment Panel III Guidelines, Circul. 110 (2004) 227-239. 
[5] N. Rifiai, G. Warnick, M. Dominiczak (Eds.), Handbook of Lipoprotein Testing, 
AACC Press, Washington, DC, 1997. 
[6] R. Lawn, Lipoprotein (a) in Heart Disease, Sci Am 266 (1992) 54-60 
[7] G. Assmann, J. A.M. Gotto, HDL Cholesterol and Protective Factors in 
Atherosclerosis, Circul. 109 (2004) 8-14. 
[8] S. Cunningham, T. McGill, A. Balfe, P. McGing, H. Grimes, N. McCarroll, in: P. 
Brown, M. Healy, A. Balfe, A. Killalea (Eds.), Guidelines on the Use of 
Biochemical Cardiac Markers and Risk Factors, ACBI, Dublin, Ireland, 2002, 
pp. 8-38. 
[9] R.S. Vasan, Biomarkers of Cardiovascular Disease, Circul. 113 (2006) 2335-
2362. 
 71 
[10] R. Vasan, Ability of Biomarkers to Predict Risk of Heart Disease, Stroke 
Appears Limited, Massachusetts General Hospital, Boston, 2006. 
[11] M. Jong, M. Hofker, L. Havekes, Role of ApoC's in Lipoprotein Metabolism: 
Functional Differences between ApoC1, ApoC2, and ApoC3, Arterioscl. 
Thromb. Vasc. Biol. 19 (1999) 472-484. 
[12] R.S. Schulman, P.N. Herbert, K. Wehrly, D.S. Fredrickson, The Complete 
Amino Acid Sequence of C-1 (ApoLp-Ser), an Apolipoprotein from Human 
Very Low Density Lipoprotein, J. Biol. Chem. 250 (1975) 182-190. 
[13] G. Assmann, J. H.B. Brewer, A Molecular Model of High Density Lipoproteins, 
Proc. Natl. Acad. Sci. USA 71 (1974) 1534-1538. 
[14] A. Hamsten, A. Silveria, S. Boquist, R. Tang, M.G. Bond, U. de Faire, J. 
Bjorkegren, The Apolipoprotein C1 Content of Triglyceride-Rich Lipoproteins 
Independently Predicts Early Atherosclerosis in Healthy Middle-Aged Men, J. 
Am. College Cardio. 45 (2005) 1013-1017. 
[15] J. Kwiterovich, Lipoprotein Heterogeneity: Diagnostic and Therapeutic 
Implications, Am. J. Card 90 (2002) 1i-10i. 
[16] K.M. Godfrey, D.J.P. Barker, Fetal Nutrition and Adult Disease, Am. J. Clin. 
Nutr. 71 (2000) 1344S-1352S. 
[17] P.O. Kwiterovich, S.L. Cockrill, D.G. Virgil, E.S. Garrett, J. Otvos, C. Knight-
Gibson, P. Alaupovic, T. Forte, L. Zhang, Z.N. Farwig, R.D. Macfarlane, A 
Large High-Density Lipoprotein Enriched in Apolipoprotein Enriched in 
Apolipoprotein C1, J. Am. Med. Assoc. 293 (2005) 1891-1899. 
 72 
[18] K. Conde-Knape, A. Bensadoun, J.H. Sobel, Overexpression of ApoC-I in ApoE-
null Mice: Severe Hypertriglyceridemia Due to Inhibition of Hepatic Lipase., J. 
Lipid Res. 43 (2002) 2136-2145. 
[19] M.C. Jong, M.J.J. Gijbels, V.E.H. Dahlmans, P.J.J.v. Gorp, S.-J. Koopman, M. 
Ponec, M.H. Hofker, L.M. Havekes, Hyperlipidemia and Cutaneous 
Abnormalities in Transgenic Mice Overexpressing Human Apolipoprotein C1. , 
J. Clin. Invest 101 (1998) 145-152. 
[20] N.S. Shachter, T. Ebara, R. Ramakrishnan, G. Steiner, J.D. Smith, Combined 
Hyperlipidemia in Transgenic Mice Overexpressing Human Apolipoprotein C1, 
J. Clin. Invest 98 (1996) 846-855. 
[21] J. Bjorkegren, A. Silveira, S. Boquist, R. Tang, A. Hamsten, Postprandial 
Enrichment of Remnant Lipoproteins with Apo C1 in Healthy Normolipidemic 
Men with Early Asymptomatic Atherosclerosis, Arterioscl. Thromb. Vasc. Biol. 
22 (2002) 1470-1474. 
[22] J. Bjorkegren, S. Bloquist, A. Samnegard, Plasma Triglyceride and the Risk for 
Vascular Disease, Circul. 101 (2000) 227-230. 
[23] A. Kolmakova, J. Kwiterovich, D. Virgil, Apolipoprotein C1 Induced Apoptosis 
in Human Aortic Smooth Muscle Cells via Recruiting Neutral 
Sphingomyelinase, Arterioscl. Thromb. Vasc. Biol. 24 (2004) 264-269. 
[24] I. Espinosa, Differential Density Lipoprotein Profiling for the Characterization of 
Lipoprotein(a), vol. Ph.D. Dissertation, Texas A&M University, College Station, 
TX, 2005. 
 73 
[25] G.D. Birnie, Isopycnic Centrifugation in Ionic Media, Biochem. Soc. Trans. 8 
(1980) 513-515. 
[26] B. Hosken, Density Gradients Ultracentrifugation of Lipoproteins Using Metal 
Ion Complex Solutes, vol. Ph.D. Dissertation, Texas A&M University, College 
Station, TX, 2002. 
[27] B. Hosken, S. Cockrill, R. Macfarlane, Metal Ion Complexes of EDTA: A Solute 
System for Density Gradient Ultracentrifugation Analysis of Lipoproteins, Anal. 
Chem. 77 (2005) 200-2007. 
[28] J. Johnson, N. Bell, E. Donahoe, R.D. Macfarlane, Metal Ion Complexes of 
EDTA as Solutes for Density Gradient Ultracentrifugation: Influence of Metal 
Ions, Anal. Chem. 77 (2005) 7054-7061. 
[29] J.R. Lakowicz, Principles of Fluorescence Spectroscopy, 2nd ed., Kluwer 
Academic/Plenum, New York, 1999. 
[30] A. Chattopadhyay, Chemistry and Biology of n-(7-nitrobenz-2-oxa-1,3-diazol-4-
yl)-labeled Lipids: Flourescent Probes of Biological and Model Membranes, 
Chem. Phys. Lipids 53 (1990) 1-15. 
[31] I. Cruzado, A. Hu, R.D. Macfarlane, Influence of Dodecyl Sulfate Ions on the 
Electrophoretic Mobilities of Lipoprotein Particles Measured by HPCE, J. Cap. 
Elec. 3 (1996) 25-29. 
[32] A. Hu, I. Cruzado, R.D. Macfarlane, Developing High-Performance Capillary 
Electrophoresis Methods for Lipoprotein Profiling, Am. Lab. 180 (1996) 18N-
18R. 
 74 
[33] P.J. Hansen, Analysis of Proteins by Immunoprecipitation, vol. Protocol, 
University of Florida, Orlando, 2006. 
[34] E.A. Kabat, The Molecular Weight of Antibodies, J. Exp. Med 69 (1938) 103-
118. 
[35] X.H. Qi, J.Q. Mi, X.X. Zhang, W.B. Chang, Design and Preparation of Novel 
Antibody System and Application for the Determination of Heroin Metabolites in 
Urine by Capillary Electrophoresis, Anal. Chim. Acta. 551 (2005) 115-123. 
[36] R. Leggett, E.E. Lee-Smith, S.M. Jickells, D.A. Russell, "Intelligent" 
Fingerprinting: Simultaneous Identification of Drug Metabolites and Individuals 
by Using Antibody-Functionalized Nanoparticle., Angew. Chem. Int. Ed. 46 
(2007) 4100-4103. 
[37] G. Dandulakis, J.C. Herr, D.J. Kirwan, Cell Growth and Monoclonal Antibody 
Production in the Presence of Antigen and Serum, Biotechnol. Prog. 11 (1995) 
518-524. 
[38] L. Borque, L. Bellod, A. Rus, M.L. Seco, F. Galisteo-Gonzales, Development 
and Validation of an Automated and Ultrasensitive Immunoturbidemetric Assay 
for C-Reactive Protein, Clin. Chem. 46 (2000) 1839-1842. 
[39] H.L.V. Epps, Michael Heidelberger and the Demystification of Antibodies, J. 
Exp. Med 203 (2006) 5-6. 
[40] I. Espinosa, C.J. McNeal, R.D. Macfarlane, Method for Lipoprotein(a) Density 
Profiling by BiEDTA Differential Density Lipoprotein Ultracentrifugation Anal. 
Chem. 78 (2005) 438-444. 
 75 
[41] D.D. Richman, P.H. Cleveland, M.N. Oxman, K.M. Johnson, The Binding of 
Staphylococcal Protein A by the Sera of Different Animal Species, J. Immunol. 
128 (1962) 2300-2305. 
[42] D. Song, D. Forciniti, Effects of Cosolvents and pH on Protein Adsorption on 
Polystyrene Latex: A Dynamic Light Scattering Study, J. Colloid Interface Sci. 
221 (2000) 25-37. 
[43] S.R. Shi, M.E. Key, K.L. Kalra, Antigen Retrieval in Formalin-fixed, Paraffin-
embedded Tissues: An Enhancement Method for Immunohistochemical Staining 
Based on Microwave Oven Heating of Tissue Sections, J. Histochem. Cytochem. 
39 (1991) 741-748. 
[44] S.R. Shi, R.J. Cote, C.R. Taylor, Antigen Retrieval Immunohistochemistry: Past, 
Present, and Future, J. Histochem. Cytochem. 45 (1997) 327-343. 
[45] M.C. Cheung, J.J. Albers, Characterization of Lipoprotein Particles Isolated by 
Immunoaffinity Chromatography, J. Biol. Chem. 259 (1984) 12201-12219. 
[46] M. Heidelberger, F.E. Kendall, C.M.S. Hoo, Quantitative Studies on the 
Precipitin Reaction, J. Exp. Med 58 (1933) 137-152. 
[47] D.W. Renn, Agar and Agarose: Indispensable Partners in Biotechnology, Ind. 
Eng. Chem. Prod. Res. Dev. 23 (1984) 17-21. 
[48] Amersham Biosciences, CNBr-activated Sepharose 4 Fast Flow Instructions, 
Amersham Pharmacia Biotech Inc, Piscataway, NJ, 2002, pp. 1-4. 
 76 
[49] J.E. Celis, J.B. Lauridsen, B. Basse, Determination of Antibody Specification by 
Western Blotting and Immunoprecipitation, in: J.E. Celis (Ed.), Cell Biology: A 
Laboratory Handbook, vol. 2, Academic Press, New York, 1994, pp. 305-313. 
[50] K. Nakajima, M. Okazaki, A. Tanaka, C.R. Pullinger, T. Wang, T. Nakano, R.J. 
Havel, Separation and Determination of Remnant-like Particles in Human Serum 
Using Monoclonal Antibodies to Apo B-100 and Apo A-1, J. Clin. Lig. Assay 19 
(1996) 177-183. 
[51] P.V. Bondarenko, Z.N. Farwig, C.J. McNeal, R.D. Macfarlane, MALDI- and 
ESI-MS of the HDL Apolipoproteins; New Isoforms of ApoA-I, II, Int. J. of 
Mass Spectrom. 219 (2002) 671-680. 
[52] M.S. Wroblewski, J.T. Wilson-Grady, M.B. Martinez, R.S. Kasthuri, A 
Functional Polymorphism of Apolipoprotein C1 Detected by Mass Spectrometry, 
FEBS Lett. 273 (2006) 4707-4715. 
[53] M.Y. Liu, C.J. McNeal, R.D. Macfarlane, Charge Density Profiling of 
Circulating Human Low-density Lipoprotein Particles by Capillary Zone 
Electrophoresis, Electrophoresis 25 (2004) 200-207. 
[54] Human Apolipoprotein C1 Product Specification, Academy Bio-medical 
Company, Houston, 2007. 
 
 
 
 
 
 
 77 
APPENDIX A 
 
Coupling Antibody to CNBr-Activated Sepharose 
This protocol is to be followed to obtain an Antibody-Sepharose gel to be coupled 
with human serum. 
Materials 
1mL Eppendorf tubes 
Coupling Buffer – 0.1M NaHCO3 
Antibody solution 
CNBr-Activated Sepharose 
1mM HCl 
Blocking Buffer - 1M Tris-Base, pH 9.0 in coupling buffer 
M-60 Orbital Shaker 
Procedure 
1. Using 300µL, carefully add antibody solution to a micro well plate and measure 
absorbance at 280nm to determine protein concentration. 
2. In a 1.5mL Eppendorf tube, add 62.5µL coupling buffer (0.1M NaHCO3 and 
0.5M NaCl, pH 9.0) to 125uL antibody solution. 
3. In a second 1.5mL Eppendorf tube, swell the Sepharose beads in 600µL 1mM 
HCl for approx. 15 min at room temperature. 
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4. Remove supernatant and wash with 600µL 1mM HCl solution for 1 min. Vortex 
tube for 1 minute at 1400rpm, allow gel to settle, and remove supernatant. 
Repeat. 
**The next two steps should be done with no pausing in between steps 5 and 6. 
5. Wash gel with 1mL coupling buffer.  Vortex tube for 1 min, allow gel to settle 
and remove supernatant. 
6. Using a clean pipette tip, transfer the antibody solution to the tube containing 
Sepharose beads.  Vortex the samples briefly to homogenize the solution. 
7. Rotate the tube gently using the M-60 Orbital shaker set to 13,000rpm at room 
temperature for 4 hours. 
8. Spin down beads using a table-top centrifuge for 1min at 2000rpm. Remove 
supernatant and take OD280. If OD280 is at least 10-fold lower than in step 1, 
continue with procedure. If OD280 is not at least 10-fold lower than in step 1, 
coupling did not proceed as expected. (Mainly caused by not transferring gel to 
antibody solution quickly enough.) 
9. Wash Sepharose beads with 1mL coupling buffer. Vortex tube for 1 min, allow 
gel to settle and remove supernatant. Repeat twice. 
10. Add 1mL blocking buffer (1M Tris-Base, pH 9.0 in coupling buffer). Vortex tube 
for 1 minute and allow to stand for 2 hours at room temperature. 
11. Remove the supernatant and wash the gel 4 times, alternating between low pH 
wash buffer (0.1M HCl, 0.5M NaCl) and high pH wash buffer (coupling buffer). 
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(2x low pH and 2x high pH) The first and fourth washes were saved and the 
OD280 of each was checked. (The OD280 readings should be below ~0.01) 
12. After removal of the supernatant, the gel is washed with Coupling buffer and is 
ready to be coupled with serum. 
 
Coupling Serum to AB-Sepharose Beads 
This protocol is to be followed to obtain a lipoprotein-depleted serum sample and a 
lipoprotein-recovered serum sample. 
Materials 
1.5mL Eppendorf tubes 
Coupling Buffer - 0.1M NaHCO3, 0.5M NaCl, pH 8.3 
1mM HCl 
Procedure 
1. Obtain AB-Sepharose gel that was freshly made. 
2. Mix 50µL serum, 10µL 1mg/mL NBD, and 600µL 0.05M Tris-HCl in a 1.5mL 
Eppendorf tube.  
3. Wash gel with 1mL coupling buffer (0.1M NaHCO3, 0.5M NaCl, pH 8.3). 
Vortex for 1 min, allow the gel to settle and remove supernatant. 
4. Using a clean pipette tip, transfer the serum mixture into the tube containing the 
AB-Sepharose beads. 
5. Gently rotate the tube for 4 hours using a M-60 Orbital shaker set to 14,000rpm 
at room temperature. 
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6. Allow gel to settle for approx. 15 min. Remove supernatant (~600uL).  Wash gel 
with coupling buffer prior to recovery. 
7. To recover lipoproteins bound to the Sepharose-Antibody gel, add 600µL 1mM 
HCl to the Eppendorf tube. Gently rotate the tube at 37°C at 1400rpm for 5 
hours. 
8. Allow gel to settle for approx. 15 minutes. Remove the supernatant (~600µL).  
Wash the gel in coupling buffer and store in 20% ethanol to prevent microbial 
growth. 
 
Concentration of Depleted and Recovered-Lipoprotein Samples 
This protocol is used to concentrate lipoprotein samples prior to ultracentrifugation. 
Materials 
3,000 molecular weight cut-off filter 
Table top centrifuge 
1.5mL Eppendorf tubes 
Density gradient 
Procedure 
1. Transfer 300µL of the depleted serum solution to a 3,000 molecular weight cut-
off filter.   
2. Centrifuge for 3 minutes at 6,000 rpm. Discard filtrate (bottom chamber).   
3. Add 400L of density gradient. Repeat until initial sample volume has been 
replaced 2.5 times.   
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4. Concentrate sample by centrifuging for 7 minutes at 6,000 rpm. 
5. Recover depleted-serum sample by inverting the top chamber of the filter into a 
clean Eppendorf tube and centrifuging for 8 minutes at 10,000 rpm. 
6. 50µL of the concentrated supernatant, 40µL dH2O, 10µL 1mg/mL NBD and 
1100uL 0.175M Cs2CdY were mixed and allowed to stain for 30 minutes.   
7. Aliquot 1000µL solution to an ultracentrifuge tube.  Follow UC protocol 
established for the density gradient used.  For 0.3M Cs2CdEDTA, tubes were 
spun at 120,000rpm at 5°C for 6 hours. 
8. After the ultracentrifugation spin, tubes were removed, layered with 200µL of 
dH2O, and digitally imaged. 
 
Imaging of UC tubes for Apo C-1-Enriched HDL 
1. Use the Optronics Microfire Camera (System II) using the BG12 filter for NBD 
excitation and OG515 for emission. 
2. Increase the exposure time from 15.8 ms to 50 ms. This will increase the Lp(a) 
peak fluorescent intensity. Keep the exposure time at 15.8 if sample is to be 
compared with a lipoprotein density profile. 
3. All other settings are to be kept the same. Target intensity of 30%, Gain of 1.000, 
MONO and 12 Bit Snap adjustment. 
4. Take the picture, save the picture, and obtain a lipoprotein profile using Origin 
7.0 
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